These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 17181919)
1. Polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. Effect of intramuscular administration in a double blind placebo-controlled clinical trial. Furuzawa-Carballeda J; Fenutria-Ausmequet R; Gil-Espinosa V; Lozano-Soto F; Teliz-Meneses MA; Romero-Trejo C; Alcocer-Varela J Clin Exp Rheumatol; 2006; 24(5):514-20. PubMed ID: 17181919 [TBL] [Abstract][Full Text] [Related]
2. Subcutaneous administration of polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. An open-label pilot trial. Furuzawa-Carballeda J; Cabral AR; Zapata-Zuñiga M; Alcocer-Varela J J Rheumatol; 2003 Feb; 30(2):256-9. PubMed ID: 12563677 [TBL] [Abstract][Full Text] [Related]
3. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.]. Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321 [TBL] [Abstract][Full Text] [Related]
4. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195 [TBL] [Abstract][Full Text] [Related]
5. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396 [TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178 [TBL] [Abstract][Full Text] [Related]
7. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB; Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469 [TBL] [Abstract][Full Text] [Related]
8. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661 [TBL] [Abstract][Full Text] [Related]
9. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J; Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810 [TBL] [Abstract][Full Text] [Related]
10. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE; Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697 [TBL] [Abstract][Full Text] [Related]
11. A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Wei W; Zhang LL; Xu JH; Xiao F; Bao CD; Ni LQ; Li XF; Wu YQ; Sun LY; Zhang RH; Sun BL; Xu SQ; Liu S; Zhang W; Shen J; Liu HX; Wang RC Arthritis Res Ther; 2009; 11(6):R180. PubMed ID: 19951408 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis. Zhang LL; Wei W; Xiao F; Xu JH; Bao CD; Ni LQ; Li XF Arthritis Rheum; 2008 Jul; 59(7):905-10. PubMed ID: 18576295 [TBL] [Abstract][Full Text] [Related]
13. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC; Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627 [TBL] [Abstract][Full Text] [Related]
14. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Mease P; Strand V; Shalamberidze L; Dimic A; Raskina T; Xu LA; Liu Y; Smith J Ann Rheum Dis; 2012 Jul; 71(7):1183-9. PubMed ID: 22328739 [TBL] [Abstract][Full Text] [Related]
15. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258 [TBL] [Abstract][Full Text] [Related]
16. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413 [TBL] [Abstract][Full Text] [Related]
17. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367 [TBL] [Abstract][Full Text] [Related]
18. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435 [TBL] [Abstract][Full Text] [Related]
19. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate. Ogrendik M South Med J; 2007 Feb; 100(2):135-9. PubMed ID: 17330681 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]